| Identification | Back Directory | [Name]
AZD 5718) | [CAS]
2041075-86-7 | [Synonyms]
Atuliflapon
Cyclohexanecarboxamide, 2-[4-(5-methyl-1H-pyrazol-3-yl)benzoyl]-N-(4,5,6,7-tetrahydro-4-oxopyrazolo[1,5-a]pyrazin-3-yl)-, (1R,2R)- | [Molecular Formula]
C24H26N6O3 | [MOL File]
2041075-86-7.mol | [Molecular Weight]
446.5 |
| Chemical Properties | Back Directory | [Boiling point ]
851.1±65.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 125 mg/mL (279.96 mM; Need ultrasonic) | [form ]
Solid | [pka]
13.12±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease[1]. | [in vivo]
Atuliflapon exhibits t1/2 of 0.45 h and 2.1 h in rat and dog by iv injection, respectively[1].
Atuliflapon shows no inhibition of 5-LO pathway activity in rodent blood[1]. | [References]
[1] Daniel Pettersen, et al. Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. J Med Chem. 2019 May 9;62(9):4312-4324. DOI:10.1021/acs.jmedchem.8b02004 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|